Vogenx appoints Ken Toombs to board of directors

Vogenx, Inc. (Nasdaq: VOGX) announced the appointment of Ken Toombs to its Board of Directors, effective September 21, 2026.¹ The company is a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases.¹

According to the company's 8-K filing, the Board appointed Toombs as a Class II director, to serve until the 2028 annual meeting of stockholders or until a successor is elected, or his death, resignation, or removal.¹ The Board also determined that Toombs qualifies as an independent director under Nasdaq listing rules and applicable SEC rules and regulations.¹ In addition to his board seat, Toombs was named to the Audit, Compensation, and Nominating and Corporate Governance committees, and will chair the Audit Committee.¹ Separately, the Board named Peter Pieraccini to chair the Compensation Committee, also effective September 21, 2026.¹

The filing states there are no arrangements between Toombs and any other person related to his selection, no family relationships with other directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.¹ Toombs also signed the company's standard director and officer indemnification agreement¹ and will be paid under the company's Non-Employee Director Compensation Policy.¹

Per the press release, Toombs most recently served as CEO of PA Consulting, having joined the firm in 2018 to lead its Americas business and later becoming CEO in October 2020.¹ His earlier roles included Global Head of Infosys Consulting, Deputy CEO of Capgemini Consulting, a partnership at PricewaterhouseCoopers, and senior positions at IBM.¹

Vogenx's lead candidate, mizagliflozin, is described as an investigational, first-in-class, orally administered, minimally absorbed small molecule inhibitor of SGLT1¹, being developed for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's Syndrome.¹